8.77
-1.24%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Meribank Biotech Co
Its shares trade on Taipei Exchange under the ticker 4724.TWO. It has been listed since 16 June 2023. In the fiscal year to 31 December 2025, it reported revenue of TWD 471.8m and a net loss of TWD 81.5m. At that date it held total assets of TWD 2.88bn and shareholders' equity of TWD 1.25bn.
Meribank Biotech Co., Ltd. engages in the research and development of stem cell technologies. The company is headquartered in Taipei City, Taipei. The company went IPO on 2023-06-16. The firm is engaged in the provision of cord blood (hematopoietic stem cells) storage and application services, placenta and umbilical cord (mesenchymal stem cells) storage and application services, peripheral blood stem cell storage service and application service, and promotion of stem cell transplantation application, development of new stem cell processing technology and storage application services. The firm also develops allogeneic umbilical cord mesenchymal stem cell manufacturing and therapeutic applications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 16 Jun 2023
- Website
- meribank.com.tw ↗
Leadership
Pay as last reported
- Mr. Yogi HsuanChairman of the Board, since 2013
- Jianfang CaiVice Chairman of the Board, General Manager
- Mr. Zixian LiuDeputy General Manager
- Ms. Yuxia ChenHead of Finance & Accounting, Corporate Governance Officer
- Botong ChenDirector
- Mingzhi XuanDirector
- Jiaxiang WangIndependent Director
- Huiyue XuIndependent Director
- Bomin YangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Meribank Biotech Co Ltd offers cord blood storage services in Taipei City with a focus on hematopoietic stem cells.
- The company provides placenta and umbilical cord storage services for mesenchymal stem cells in Taiwan.
- Meribank Biotech has developed allogeneic umbilical cord mesenchymal stem cell manufacturing and therapeutic applications.
Weaknesses
- Meribank Biotech Co Ltd's IPO on 16 June 2023 may limit initial market expansion in Taiwan.
- The company's stem cell storage services are currently limited to Taipei City and Taiwan.
- Meribank Biotech's focus on stem cell applications may face regulatory challenges in the Health Care sector.
Opportunities
- Expanding cord blood storage services to other regions in Taiwan could increase market reach.
- Developing new stem cell processing technology may attract international partnerships.
- Growing demand for stem cell therapies in the Health Care sector presents a significant opportunity.
Threats
- Regulatory changes in Taiwan's Health Care sector could impact stem cell storage services.
- Competition from other biotech firms in the Information Technology sector may arise.
- Economic downturns in Taiwan might reduce investment in stem cell research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.